ArticleBMC infectious diseases2026
Baseline cohort profile: clinical and molecular characterisation of SARS-CoV-2 infected patients recruited into a longitudinal COVID-19 cohort study (COVGEN) in Malaysia.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
Abstract
backgroundA COVID-19 patient cohort study (COVGEN) was established in Malaysia to investigate the association between viral genetic variants, host risk factors, and COVID-19 severity. The COVGEN study is prospective, longitudinal, multicentre study and was conducted in Cheras, Kuala Lumpur, at the COVID-19 Assessment Centre in Bandar Tun Razak, Hospital Canselor Tuanku Muhriz (HCTM), and UKM Medical Molecular Biology Institute (UMBI).
objectiveHere, we report the baseline characteristics (demographic and clinical outcomes) of 2406 COVID-19 patients who enrolled in the cohort, as well as the molecular characteristics of the SARS-CoV-2 that were isolated from the participants.
methodSerial collection of biospecimens including blood, urine and swab were collected from each participant on day 0 (recruitment), with follow-up visits at three, six- and 12-months. A questionnaire was developed to assess demographic and socioeconomic characteristics, comorbidities, medical history, COVID-19 infection history, vaccination status, clinical symptoms and post-COVID-19 symptoms. Laboratory assessment included complete blood count, lipid profile and renal function tests. Molecular characterisation of SARS-CoV-2 isolated from the acute COVID-19 patients were performed using next-gene sequencing. Chi-square tests and multinomial logistic regression analyses were performed to identify risk factors associated with COVID-19 outcomes.
resultsA total of 2406 participants were enrolled in this cohort. In Malay, risk factors that were associated with severe outcome (Covid category (CAT); CAT-3, CAT-4 and CAT-5), were older age, vaccine type, vaccination status and underlying comorbidities including hypertension, chronic kidney disease, cardiovascular disease and respiratory. In Chinese, homologous vaccine regimens had higher risk to having severe outcomes than heterologous vaccine regimens. In Indian, underlying comorbidities were associated with CAT-4 outcomes. Olfactory dysfunctions were associated with infection during Delta period while sore throat was associated with infection during Omicron period.
conclusionsIn this study, comorbidities were associated with severe outcomes and mortality, whereas heterologous vaccine regimens were associated with non-severe outcomes. Distinct symptoms profiles were observed between Delta and Omicron infections. The high attrition rate highlighted a challenge in conducting longitudinal study in Malaysia. Nonetheless, this study provides a valuable resource for future research on COVID-19 disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.